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Abstract
Background. Proteinuria is a characteristic feature of severe acute pancreatitis (SAP) that may allow unique insights into AP
pathophysiology. This study used a proteomic approach to differentiate the abundant urinary proteins in AP patients.
Materials and methods. Urine samples were prospectively collected from 4 groups (5 SAP, 10 mild gallstone AP, 7 mild
alcohol AP, 7 controls). Reverse-phase high-performance liquid chromatography (RP-HPLC) and matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (LC MALDI) were used to identify urinary proteins and determine
any differences between the groups. Results. There were 17 RP-HPLC major peaks in SAP groups of significantly greater
absorbance magnitude than the corresponding ones in mild and control groups. Various mass spectrometry methods were
used to identify 21 different parent proteins from these SAP peaks. They included fibrinogen, serum amyloid A, insulin and
calcitonin gene-related peptides. There were no identifiable protein peaks at the corresponding elution times in the mild
pancreatitis and controls samples. Discussion. Proteomic techniques offer a unique unexplored window into AP
pathophysiology. The utility of these proteins as markers of pancreatitis severity now need to be further investigated and
the identification extended to the full urinary proteome as technology permits.
Key Words: Pancreatitis, proteome, urine
Introduction
Acute pancreatitis (AP) remains a common intra-
abdominal disease with a complex pathophysiology.
The overall outcome has improved, but specific
treatment(s) remains elusive. The challenge is the
early identification and treatment of patients who will
develop severe acute pancreatitis (SAP) and infected
pancreatic necrosis. This study documents the devel-
opment of a new approach to investigating the
pathophysiology of AP by applying laser desorption/
ionization time-of-flight mass spectrometry (LC
MALDI) proteomic techniques to urine from these
patients.
The science of proteomics defines the protein
complement expressed by the genome, the so-called
proteome [1]. It is a powerful tool that not only
identifies peptides and proteins, but also quantifies
their up- and down-regulation. The isolation of
proteins from complex mixtures has been possible
using techniques including high performance liquid
chromatography (HPLC) and two-dimensional poly-
acrylamide gel electrophoresis (2D PAGE). Subse-
quent identification of proteins and peptides has
historically been more problematic and relied on N-
terminal amino acid sequencing by Edman degrada-
tion. Although a robust and tested method, this
technique is time-consuming, expensive and requires
relatively large amounts of very pure protein sample.
Proteomics has come of age because of two key
developments: soft ionization mass spectrometers,
which can now rapidly define the molecular weights
and amino acid sequences of peptides from relatively
small quantities of complex sample mixture [2] and
publicly available databases that can identify proteins
directly from these peptide fragment masses [3].
The proteinuria associated with pancreatitis is well
recognized but neither fully understood nor system-
atically characterized. Low molecular weight proteins
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have been demonstrated in the urine during the acute
phase of the disease, but these were absent later in the
recovery period [4]. Others have shown that micro-
albuminuria during the first 36 h of hospital admis-
sion was likely to be associated with more serious
complications [5]. Subsequent studies have tended to
identify specific isolated urinary proteins in patients
with AP, including trypsinogen activated peptide
(TAP) [6], carboxypeptidase A [6], thyrotropin re-
leasing hormone [7], hydroxyproline and fibronectin
[8]. However, the characterization of the complete
urinary proteome in AP has yet to be accomplished
and is likely to be difficult due to the variability of
proteins in urine, both qualitative and quantitative
[9]. The low abundance and post-translational
modification of urinary proteins means that tradi-
tional proteomic techniques such as 2-DE PAGE and
Edman sequencing are not as useful as when these
techniques are applied to studies of serum and tissue
samples.
The aim of this study was to investigate the utility of
a recently acquired LC MALDI proteomic technology
platform in the identification of high abundance
urinary proteins in patients suffering from AP.
Materials and methods
Study population
Adult patients with a primary episode of AP as
defined by abdominal pain associated with either a
serum amylase 1000 U/L or computed axial tomo-
graphy scans (CT) demonstrating pancreatic inflam-
mation/necrosis, were identified on admission to
Auckland Hospital (an 800 bed tertiary hospital
serving a 280 000 catchment population). Patients
were excluded if the duration of illness was greater
than 48 h; they were currently taking diuretic or anti-
coagulation medication; they had chronic renal failure
(pre-pancreatitis serum creatinine 0.12 mmol/L);
or they had diabetes, nephrotic syndrome, or evidence
of acute renal failure at any stage of the urinary
collection (serum creatinine 0.12 mmol/L or 24 h
urinary volume B400 ml). Normal controls were
healthy male staff volunteers. The aetiology of AP was
classified as gallstones (demonstrated by ultrasound,
endoscopic retrograde cholangiography (ERCP), or at
laparotomy), alcohol (when average daily intake ex-
ceeded 50 g, or there was a recent binge event in
the clinical history and absence of other causes), or
‘other’ (when another or no cause was identified).
‘Severe’ AP was defined as AP associated with organ
failure and/or local complications such as pancreatic
necrosis, abscess, or pseudocyst [10]. APACHE II
[11] scores were calculated at admission to assess
severity. The study was approved by the Auckland
Ethics Committee and each patient gave informed
consent.
Sample preparation
Urine was collected during each 24 h of hospitaliza-
tion, from which 20 ml aliquots were extracted for
analysis. The urine was initially centrifuged at 2000
rpm for 25 min to remove particulate material.
The supernatant was then loaded onto SepPak Plus
C18 cartridges (Waters Corporation, Milford, MA,
USA) and eluted with 4 ml of 0.1% trifluoroacetic
acid/80% acetonitrile. The acetonitrile was evapo-
rated off before injecting the residual sample volume
through a 0.20 mm filter (Sartorius MiniSart RC4
filter).
Reverse-phase high-performance liquid chromatography
Reverse-phase high-performance liquid chromatogra-
phy (RP-HPLC) was used to determine urinary
protein profiles of each patient. A 100 ml portion of
prepared urine sample was injected onto a Jupiter C18
5 m 300 A˚ 4.6 mm250 mm column (Phenomonex
NZ, Auckland) through a manual Rheodyne 200 ml
loop and Applied Biosystems 140B Solvent Deli-
very System. Buffer A comprised 0.08% (v/v) tri-
fluoroacetic acid (TFA) in MilliQ H2O and buffer
B was 80% acetonitrile/20% buffer A. The separation
gradient was 1070% buffer B over 30 min at
flow rates of 1 ml/min. Absorbance at 214 nm was
detected by 1000S Diode (AUFS 3) and traces
printed onto Yokogawa 3057 recorder. Column eluent
was collected every 30 s in 1.5 ml microcentrifuge
tubes loaded into a BioRad Model 2110 fraction
collector.
Repeat RP-HPLC purification runs were per-
formed with diluted samples when absorbance peaks
exceeded maximum AUFS scale levels. Those sam-
ples with complex peak patterns were submitted to
further RP-HPLC with a shallower buffer gradient
(2050% buffer B over 30 min) to further purify peak
components. Additional attempts were also made to
further isolate those fractions that still comprised
complex mixtures of proteins by injecting 50 ml of
the collected fraction onto a narrow bore Jupiter
reverse phase column (C18 5 m 300 A˚ 2.0 mm
250 mm column; Phenomonex). The buffer gradient
was started at 15% less than the concentration at
which the fraction initially eluted off the RP-HPLC
column, and increased to the eluting concentration
over 30 min in a previously validated method [12].
Separated peaks were collected manually.
The urinary RP-HPLC elution profile traces were
initially compared for major peak absorbance value
differences. Group differences for this and other
variables were determined by ANOVA with Tukey’s
post hoc testing, where pB0.05 was regarded as
significant (Prism 4.0 for Mac, GraphPad Software
Inc.).
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Protein sequencing
Edman degradation is a technique where individual
amino acids are sequentially cleaved from the N-
terminus of the protein and identified to give an
amino acid sequence. Acetonitrile from the RP-
HPLC fractions was removed by vacuum centrifuga-
tion. Fractions were reconstituted with an equal
volume of 0.1% TFA before 50 ml was loaded for
analysis onto Applied Biosystems Procise Sequencer
Model 610A 2.1.
Mass spectrometry
Mass spectrometry separates proteins on the basis of
their mass and can fragment them into ions that can
be used to identify the amino acid sequence. Proteins
are initially ionized by either laser ionization of a dried
crystalline mixture (matrix assisted laser desorption
ionization or MALDI), or from a solution of highly
charged droplets sprayed in the presence of a strong
electric field (electrospray ionization or ESI). The
ions may then be accelerated along a flight tube that
separates them by their varying velocities based on
individual mass-to-charge ratios (the so-called time-
of-flight or TOF). A certain degree of ion fragmenta-
tion occurs along the flight tube due to inherent ion
instability and post-source decay (PSD). PSD can be
used to determine amino acid sequence and can be
enhanced by chemical-assisted fragmentation (CAF)
(EttanTM CAFTM MALDI Sequencing Kit, Amersham
Biosciences), which adds a sulphydryl group to the N-
terminus of tryptic digested peptides, augmenting the
PSD signal of y-series ions. A further advancement is
the quadrupole time-of flight (Q-TOF) technique that
gives a more reproducible and characteristic fragment
pattern that enables identification of amino acid
sequences when used in conjunction with computer-
ized databases such as Mascot and ProID.
In this current study all fractions were trypsin
digested before mass spectrometry. The fractions
were reconstituted in 50 ml of 100 mM ammonium
bicarbonate before the addition of 0.5 mg sequencing
grade porcine trypsin (Promega; 0.5 ml of 1 mg/ml in
1% acetic acid). The solution was then incubated at
378C for 2 h before the reaction was stopped by the
addition of 1 ml of 100% TFA. The solution was
vacuum centrifuged to near dryness and the protein
was reconstituted in 0.1% TFA. Tryptic peptides
were sulphonated with Ettan CAF-MALDI sequen-
cing kit (Amersham Biosystems, Uppsala, Sweden) to
enhance PSD identification. In brief, peptides were
bound to a prepacked reverse-phase C18 matrix in
pipette tips (ZipTipTM, Millipore Australia Pty Ltd,
Sydney, Australia) and O-methylisoureahydrogen sul-
phate solution (pH11.7) was loaded onto the
ZipTipTM. Tips were incubated in a sealed tube at
378C for 2 h to block the o-amino group of lysine
residues and leave the N-terminal amino group intact.
Freshly made CAF-labelling reagent was then loaded
onto the ZipTipTM and allowed to react for 3 min at
room temperature to sulphonate the N-terminus. The
ZipTipTM was washed of excess CAF-labelling reagent
and the derivatized peptide was eluted for further
analysis. The sulphonation adds 136 Da to peptides
containing a C-terminal arginine.
MALDI-TOF PSD was performed on an Applied
Biosystems Voyager DE-PRO. Fractions were recon-
stituted with 0.1% TFA, mixed 1:1 in 1% a-cyano-4-
hydroxycinnamic acid (aCHCA), spotted onto a
Teflon plate (0.5 ml) and allowed to dry at room
temperature. Protein masses were determined in
positive reflector mode, accelerating voltage 20 000
V, grid voltage 6275%, mirror voltage ratio 1.12,
guide wire 0.002%, extraction delay time 50 ns, laser
intensity 20003000, laser repetition rate 20 Hz,
acquisition mass range 75010 000 Da. Near-point
external mass calibrations were performed daily with
angiotensin and insulin standards.
For PSD analysis the instrument was set for PSD
and the ion selector was set to the m/z values of the
precursor ions sequentially. The number of voltage
segments required was determined by the precursor
ion mass and the lowest mass to be analysed. PSD
spectra were thus acquired in a set of 1018 spectra
using decreasing reflector voltages. Laser power was
adjusted so that unit mass resolution was maintained,
and 100300 laser shots were collected for each
voltage segment. The resultant spectra were manually
interpreted by measuring the masses between each
y-ion peak, and the resultant amino acid sequence was
entered into NCBI protein-protein BLAST search
(www.ncbi.nlm.nih.gov/BLAST).
ESI-Q-TOF was performed on a quadrupole
orthogonal acceleration time-of-flight tandem mass
spectrometer (QSTAR XL, Applied Biosystems).
Tryptic peptides were analysed by electrospray ioniza-
tion in the Q-TOF mass spectrometer using a
nanoelectrospray ion source. The capillary voltage
was set to 1800 V and the curtain gas was set at 15
(Units). Low-energy collision-induced dissociation
was performed using nitrogen as a collision gas at a
recorded pressure of 6 psi, and the collision energy
was optimized for different by ramping up the Q0
energy. Data acquisition was controlled by Analyst QS
software (Applied Biosystems) using an automated
acquisition mode for MS and MS/MS experiments.
Obtained spectra were searched against a database
using Pro ID with confidence73%. Any matches
were then checked against Mascot database where
pB0.05 was taken as proof of identity.
Results
Urine samples were collected from 5 patients with
severe acute pancreatitis (SAP) (median age 69 years,
range 6078, 5 males), 10 patients with gallstone mild
acute pancreatitis (MAP) (median age 65 years, range
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4478, 7 males) and 5 patients with alcohol MAP
(median age 39 years, range 1958, 4 males), and 7
control subjects (median age 42 years, range 3550, 7
males). Patient samples were collected on the first day
of admission. The 24 h urine volume of SAP patients
was 9049272 ml (mean9SEM); gallstone MAP was
5559175 ml; alcohol MAP was 6069118 ml (p
0.45, one-way ANOVA). One patient died (SAP).
The hospital stay for SAP was median 31 days, range
2100, median 4 days, range 36 (gallstone MAP),
and median 5 days, range 27 (alcohol MAP),
respectively. The APACHE II score for the SAP
group on admission was 10.491.5 (mean9SEM),
2.290.6 (gallstone MAP), and 0.690.3 (alcohol
MAP) (pB0.0001). SAP was caused by gallstones
(two patients), alcohol (one), and other (two pa-
tients). All SAP patients were admitted to intensive
care for nutritional support (one total parenteral and
four enteral nutrition) and prophylactic antibiotics
(meropenem; Merrem, AstraZeneca, Australia) were
given to all of them. Three SAP patients eventually
had surgical intervention later in their admission
for infected pancreatic necrosis, one had percuta-
neous drainage of acute fluid collection, one had an
endoscopic retrograde choledochopancreatogram,
and one required venovenous dialysis after 5 days of
admission.
RP-HPLC
There was no single common pattern to the RP-
HPLC elution peak profile in any group, nor could a
single pattern be used to discriminate between the
aetiological subgroups. However, there were 17 major
peaks in the SAP group traces that had significantly
greater absorbance unit (AU) values at 214 nm than
those at identical elution times in both the mild
groups and controls (Figure 1). These peaks eluted
at differing buffer concentrations spanning unique
positions at 2243% buffer B and had an AU mean
of 2.3290.22 (9SEM) compared with those peaks
from an equivalent extracted urine volume and
elution time in the other groups (0.4990.23 for
mild gallstone AP, 0.1990.04 for mild ethanol AP,
and 0.2090.04 for controls, respectively, pB0.0001).
These large peaks were invariably found to contain a
complex mixture of proteins and further RP-HPLC
was able to partially resolve the individual protein
components.
Edman sequencing
Three peaks were initially submitted for Edman
degradation sequencing. Only one peptide was suc-
cessfully sequenced and it was identified as collagen
a1 (I) precursor.
Mass spectrometry
Of the 160 spectra obtained, 77 (48%) could be
identified manually or by database searches. All
proteins required trypsin digestion for CAF modifica-
tion and database searching from ESI Q-TOF. There
were 77 peptide sequences identified from the 17
major peaks isolated by HPLC above; 23 were
identified by MALDI-TOF PSD with CAF, and 43
by ESI Q-TOF alone. These peptides corresponded
to 21 different proteins (Table I). Of note, collagen I
(a1 and a2) chains and fibrinogen sequences were
each found in four of the five SAP patients, calcitonin
gene related peptide (CGRP) in two SAP, haemoglo-
bin in two SAP, and serum amyloid A in two SAP
patients. a1 Anti-trypsin was found in three SAP
patients. No proteins were identified from the urine in
the mild cases or control urine at the same RP-HPLC
elution positions.
Interestingly, many of the peptides had significant
amino acid sequence homology yet considerable differ-
ences in apparent hydrophobicity as based on elution
time. For example, the haemoglobin B sequence
VVAGVANALAHKYH was found at 39% buffer
B, but the similar sequence VVAGVADALAHKYH
(different by only one residue at position 7 (N for D))
eluted earlier at 32% and 36%. Furthermore, many
of the peptides with identical sequences displayed
different hydrophobicities. For example, haemo-
globin B chain VVAGVANALAHKY eluted at three
different concentrations of acetonitrile (27%, 32%
and 36%) yet had the same mass (1148 Da) when
subjected to mass spectrometry.
Discussion
This study successfully demonstrated the utility of a
modern proteomic approach to SAP by identifying a
series of proteins in the urine of AP patients using
RP-HPLC and mass spectrometry. The RP-HPLC
profiles of the urine from patients with SAP collec-
tively showed 17 major peaks that were clearly
identifiable compared with those found at similar
elution times in MAP and control samples. These
marked urinary proteomic differences were present
despite there being no overt evidence of acute renal
failure at the time of collection in the SAP patients.
These major peaks contained a mixture of proteins
and peptides that were resolved to varying degrees by
mass spectrometry. The protein fragment masses
from 21 different proteins were ultimately identified,
with the most frequent being collagen I (a1 and a2)
and various fibrinogen fragments. These results are
encouraging but also demonstrate that the full pro-
teome is likely to remain a challenge due to an
inability to obtain recognizable mass signature identi-
fications on many targets. This is probably a conse-
quence of the fragmented nature of the urinary
proteins combined with the known propensity for
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multiple amino acid side chain modifications [13],
which the current databases were unable to resolve by
mass signature alone at this resolution. This limitation
is likely to be resolved in the future as computer
databases become more sophisticated hence allowing
a further unique opportunity to investigate AP.
Proteomics is a rapidly advancing field that is a
direct offshoot of the recent characterization of the
genome. Having access to a gene blueprint via openly
available databases has enabled the characterization of
proteins in a variety of human diseases and the
identification of new biomarkers. Underlying the
success of proteomics is the development of high-
throughput technologies that accurately and rapidly
identify small amounts of protein from complex
mixtures. The discovery and development of soft
ionization methods [14] for proteins has led to mass
spectrometry superseding Edman degradation for the
identification and sequencing of proteins. At the time
of commencing these studies, these techniques had
not yet been applied to AP and this study set out to
provide proof of principle that it might have future
application for research into this disease.
The two obvious fluids to investigate in pancreatitis
are serum/plasma and urine. The former presents a
particular challenge because in blood only 22 proteins
comprise 99% of the total protein [15], meaning that
low abundance proteins are difficult to isolate or to
monitor for pathological changes. One mass spectro-
metry technique (surface enhanced laser desorption
Figure 1. Representative RP-HPLC traces of urine from control, mild acute pancreatitis and severe acute pancreatitis patients. The
gradient increase of acetonitrile (ACN) concentration from 10% to 50% over 30 min is shown. Absorbance 214 nm.
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ionization or SELDI) has already been applied to the
serum of pancreatitis patients, showing that protein
profiles differ [16]. Urine offers a unique advantage in
this disease since it is a micro-filtrate of serum and is
arguably a more accessible body fluid. It is also an
extremely relevant sample source, since renal function
changes are known to be associated with AP [17].
Until recently, applying proteomics to urine has been
difficult as 2D PAGE is hindered by the low abun-
dance of proteins in normal urine, the ‘contamination’
effect of the more ubiquitous albumin, and the small
size of most urinary protein fragments. Novel app-
roaches to characterize the proteome of normal urine
have included concentration methods such as dye and
acetone precipitation [18,19], and separation techni-
ques such as protein fractionation [9]. However, these
Table I. Proteins identified in the urine of patients with acute pancreatitis.
Protein identity






a1 antitrypsin SPLFMGK 28%, 38% ESI Q-TOF
Apolipoprotein A1 DEPPQSPWDR 28%, 38% ESI Q-TOF
CGRP SNFVPTNVGSK 23%, 41% ESI Q-TOF
Chain P human platelet profilin PPPPPPPPPP 22% ESI Q-TOF
Collagen a1 (I) precursor PPGPPGPPGPPG 11% CAF PSD
AHGDRGEGP 26% Edman
GFSGLDGAK 29% ESI Q-TOF
GETGPAGPAGPIGPVGAR 33% ESI Q-TOF
GFSGLDAK 38% ESI Q-TOF
GQPGVOGFPGPKGANGEPGK 38% ESI Q-TOF
Collagen a2 (I) precursor GPAGPSGPAGKDGRR 21% CAF PSD
GLHGEFGL 30% CAF PSD
GHNGLQGLPGIAGHHGD 32% CAF PSD
IGQPGAVGPAGIR 33% ESI Q-TOF
GLPGVAGAVGEPGPLGIAG 43% CAF PSD
Collagen a2 (IV) precursor PGPPPVILPGMKDIKGEK 33% CAF PSD
Collagen a1 (XII) PGPGGRRPGFPG 38% CAF PSD
Cytotoxic T lymphocyte protein 4 GIASFVBEYASPGKATEVR 32% ESI Q-TOF
Fibrinogen VNDRWK 39% ESI Q-TOF
Fibrinogen a precursor OADEAGSEADHEGTHSTK 22% ESI Q-TOF
ESSSHHPGIAEPSR 32%, 35% ESI Q-TOF
GSESGIFTNTK 33%, 36% ESI Q-TOF
GDP-mannose 4,6 dehydratase REFPEKSFW 27% CAF PSD
Haemoglobin A chain VLSPADKTNVK 27%, 38% ESI Q-TOF
VGAHAGEYGAELER 34%, 41% ESI Q-TOF
VGAHAGEYGAEALER 36%, 38% ESI Q-TOF
TYFPHFDLSHGSAQVK 38% ESI Q-TOF
VDPVNFK 38% ESI Q-TOF
Haemoglobin B chain VVAGVADALAHKYH 32%, 36% CAF PSD
VVAGVANALAHKYH 39% ESI Q-TOF
VVAGVANALAHKY 27%, 32%, 36% ESI Q-TOF
VVAGVNAAIAH 33% CAF PSD
VNVDEVGGEALGR 39% ESI Q-TOF
SAVTALWGK 41% ESI Q-TOF
Haptoglobin precursor GSFPWQAK 39% ESI Q-TOF
Immunoglobin heavy chain AEDTAVYYCAKRPPGYSSSWER 36% ESI Q-TOF
Insulin GEFYTPK 33% ESI Q-TOF
Isocitrate dehydrogenase (S. enterica) LVRRAAIEYAITNAR 38% ESI Q-TOF
Lysine decarboxylase (S. enterica) NALGILGGPKR 27%, 33% ESI Q-TOF
Serum amyloid A SGKDPNHFRPAGLPEK 24%, 28%, 33%, 36% ESI Q-TOF
LTGHGAEDSLADQAANK 28%, 33% ESI Q-TOF
GPGGAWAAEVISNAR 29% ESI Q-TOF
DPNHFRPAGLPEK 33% ESI Q-TOF
GAEDSLADQAANK 33% ESI Q-TOF
SGRRDPNHFRPAGLPEK 33% ESI Q-TOF
FGHGAENSDANEAA 35% CAF PSD
FFGHGAEDSLADQA 39% CAF PSD
Uromodulin VLNLGPITR 36% ESI Q-TOF
CAF-PSD, chemical assisted fragmentation-post source decay; Edman, Edman degradation sequencing; ESI Q-TOF, electrospray
ionization quadrupole time-of-flight; HPLC, reverse-phase high-performance liquid chromatography; CGRP, calcitonin gene-related
peptide.
*Multiple elution (% buffer B) entries are given when the same peptide sequence was eluted at different times by HPLC.
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are time-consuming and require large amounts of
urine. Indeed, one study required 90 mg of urinary
protein (comparable to 4.5 litres of urine) to identify
124 peptides [20], making it impractical in critical
illnesses such as pancreatitis. Severe pancreatitis is
unique in that it is associated with significant protei-
nuria that negates the need for complicated concen-
trating procedures. The ability of new proteomic
technologies to circumvent these obstacles without
urine pretreatment has already been recognized [13],
but this is the first study, to our knowledge, that has
applied them to an investigation of a critical illness
like AP. We reasoned that for this first proof of
principle study a simple analysis of direct samples of
urine collected and compared from mild and severe
cases might reveal what abundant proteins appear in
the urine early in the development of a severe attack.
There was no difference in the total 24 h urine output
of any of the study groups, so we deliberately chose
not to concentrate multiple samples of normal or mild
urine to artificially increase the protein content [21],
as we were interested in what proteins appeared at
abundant levels in realistic bedside patient samples.
This would allow any findings to be transferred to the
normal clinical setting.
Proteinuria has long been recognized as a feature of
SAP and has even been proposed as a prognostic
indicator of outcome [5]. It is a reliable feature of
early disease that has led researchers to speculate that
a protein released in pancreatitis may be responsible
for the changes in renal protein handling [4]; a
tantalizing hypothesis that may explain the onset of
organ dysfunction in other areas. Unlike other studies
of critical illness that have discovered a high correla-
tion of albuminuria alone with severe disease [21],
this study revealed there to be a complex mixture of
urine proteins, many of them reflecting aspects of the
general inflammatory process that is occurring in early
severe pancreatitis. We found many peptide masses
that did not match the existing databases. While many
are expected to be due to chemical modifications to
the proteins, it remains possible that one or more of
these is from a potential ‘pancreatitis-specific’ novel
urinary protein. It will be interesting to make careful
comparison to the urinary proteomes of other inflam-
matory illnesses as they become available in the
future, to determine if any of these signatures are
specific to the pancreatitis process itself. It was of
note that many of the parent proteins successfully
identified through our study have been implicated
previously in AP but usually in serum. This current
study now confirms by this independent technique
their signature in urine and thereby this fluid’s
potential to be probed for their measurement.
In this study there was no clinical evidence of overt
renal failure, suggesting that the finding of these
diverse urinary proteins in severe pancreatitis is an
early feature and therefore worthy of close investiga-
tion for its prognostic utility. The spectrum of
proteins displayed in the first 24 h of admission by
the urine was entirely consistent with the evolving
inflammatory process and confirms that this will likely
be a useful new viewpoint for monitoring the evolu-
tion of the disease. For instance, serum amyloid A
(SAA) is an acute phase reactant that has been
implicated as a modulator of neutrophil function
and oxidative injury in acute inflammation [22]. Its
role in pancreatitis has not been defined but elevated
serum levels have been found to be a better predictor
of outcome than C-reactive protein (CRP) [23]. To
the best of our knowledge, this study is the first to
describe the presence of an SAA signature in the urine
of critically ill pancreatitis patients, and invites further
investigation into its role and measurement in the
urine as a severity indicator. In a similar manner,
fibrinogen and its fragments have also been postulated
as a predictor of outcome in AP, yet efforts with
plasma measurements have been disappointing
[24]. The findings we report here of readily identifi-
able fibrinogen-derived peptides in the urine of severe
pancreatitis patients may therefore offer an alterna-
tive matrix in which to re-investigate the predictive
value.
The presence of collagens I and IV in this study is in
keeping with experimental studies into pancreatitis
pathogenesis. Products of lipid peroxidation stimulate
fibroblasts to synthesize increased levels of collagen I
[25] that have been shown in the peri- and intra-
lobular regions of mouse pancreas 4 days after the
intraductal injection of trypsin [26]. These have yet to
be confirmed in human studies and our findings
would point to the potential utility of urinary col-
lagens as an early measurable change in human SAP.
Several unusual targets were identified and in-
cluded peptides identified as belonging to Salmonella
enterica. Surprisingly this has been associated in
various case histories of AP [27]. It is widely believed
that bacterial translocation through the intestine is a
source of infection once pancreatic necrosis has
developed, yet this study suggests that systemic
presence may occur earlier. Indeed intestinal integrity
is known to be reduced early in pancreatitis [28] and
the role of enteric bacteria such as S. enterica also
warrants further study.
The presence of insulin (pancreatic islet hormone)
and calcitonin gene-related peptides (neuropeptide)
was unexpected and to our knowledge this finding has
not been reported previously in the urine of AP
patients. It is therefore interesting to speculate on
the prognostic value of such small peptides, particu-
larly since one is of direct pancreatic origin.
Other parent proteins for the fragments described
in this study have not been associated with AP but
have been described in normal urine elsewhere.
Indeed a-1 anti-trypsin, apolipoprotein, fibrinogen,
haemoglobin, haptoglobin and uromodulin have all
been identified in proteomic studies of concentrated
normal urine [20]. Their presence in our study serves
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to validate our detection methodology. To date these
proteins have only been identified in normal urine that
has been greatly concentrated and so it seems likely
that these normal urinary proteins are excreted in
supranormal amounts in SAP given that we required
no concentration step. Whether this is due to in-
creased permeability of the glomerular filter, de-
creased proximal tubule reabsorption, or both,
cannot be determined from this study. This raises
the possibility that a spot urinalysis demonstrating
these proteins could be an early indicator of renal
involvement in the course of SAP before creatinine
deteriorates.
Although this study was successful in overcoming
some historical problems in identifying urinary pro-
teins, it has raised a series of further interesting issues.
First, there were several instances where mass mea-
surements of some protein fragments indicated that
they had undergone substantial and variable post-
translational modifications. This problem has been
reported before [20,29]. The vast number of chemical
modifications that include peptide oxidation, deami-
dation and carbamylation make many of the obtained
mass spectrometry spectra in our study currently
indecipherable. To overcome the problem of modifi-
cations and fragmentation, we used tryptic digestion
to enable database recognition of unaltered or pre-
dictably altered smaller fragments. The main limita-
tion that remains for this approach is the mass
accuracy of mass spectrometers coupled with the
capacity of the computerized databases to interpret
peptide fragments and their chemical modifications,
but it is conceivable that this will be resolved as new
mass spectrometry technologies such as Fourier
transformed mass spectrometry (FTMS), with in-
creased mass accuracy down to 0.002 Da (2 ppm), are
applied to biological samples and subsequent data-
base resolution advances.
In an attempt to improve the identification process
this study used ‘chemically assisted fragmentation’ to
try to solve the problem of modified protein identifi-
cation. Eliminating all but the ‘y ions’ from the mass
spectrometry spectrum allows the mass of the mod-
ification to be isolated by simple manual interpreta-
tion. Furthermore, it enhanced fragmentation of the
peptide that was generally poor with MALDI-TOF
PSD. This technique has been reported in de novo
sequencing before [30] but never applied to urinary
proteins.
Another inherent limitation of the techniques
described in this current study was the need to trypsin
digest all the urinary protein before identification.
Although successful, our techniques did not allow
direct identification of all of the initial parent mole-
cules that supplied the subsequent trypsin-digested
fragments. We could not therefore quantify to what
extent the initial proteins were present in more than
one modified state; although the multiple similar
fragments and variable retention times suggest that
this was probably a common occurrence.
In conclusion, this feasibility study has successfully
applied recent proteomic techniques to identify many
of the abundant protein signatures present in the
urine of patients developing severe pancreatitis. De-
spite the limitations of mass resolution on current
machines, databases and the intrinsic challenges of
working with proteins in a urine matrix, this study
provides the first key steps toward identifying the
entire urinary proteome in AP. It also provides
evidence that through the tools of modern mass
spectrometry the urine now offers an exciting, albeit
challenging new window into the pathogenesis of
SAP. Encouraged by these findings the next task
should be evaluation of these and other less abundant
urinary proteome targets for their relative efficacy as
severity markers and possible new directions for
therapeutic design.
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